Recursion Reports Reduced Polyp Burden in REC-4881 Phase 2 Study
Recursion reported a reduction in median polyp burden in a Phase 2 study of REC-4881.
Related stories
Samsung Biologics Signs $324.8 Million Drug Manufacturing Contract
Samsung Biologics signed a drug manufacturing contract worth USD 324.8 million.
M impact | EQUITY | Nov 02, 2026, 11:37 PM UTC
Ero Copper Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Nov 02, 2026, 11:36 PM UTC
PLDT Auditor SGV Resigns Over Independence Concerns
PLDT’s auditor, SyCip Gorres Velayo (SGV), resigned, citing a lack of independence.
M impact | EQUITY | Nov 02, 2026, 11:34 PM UTC
Argentine Stocks Fall for Sixth Straight Session as Country Risk Tops 800
Argentine shares fell for a sixth consecutive session, country risk exceeded 800 points and the central bank did not buy reserves.
M impact | EQUITY | Nov 02, 2026, 11:34 PM UTC
Axsome Therapeutics Shares Hit 52-Week Low as Much as 15%
Axsome shares fell as much as 15% on Monday as investors focused on Auvelity launch pacing in Alzheimer’s disease agitation, despite the company’s strong third-quarter report.
M impact | EQUITY | Nov 02, 2026, 11:32 PM UTC
Dow Jones and Nasdaq Reverse From Monday Highs
Wall Street benchmarks reversed after opening higher, with the Dow ending up 200 points while technology shares sold off, according to the report.
M impact | EQUITY | Nov 02, 2026, 11:31 PM UTC